Analysts’ Top Healthcare Picks: Solid Biosciences (SLDB), Universal Health (UHS)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Solid Biosciences (SLDB – Research Report) and Universal Health (UHS – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Solid Biosciences (SLDB)
William Blair analyst Lachlan Hanbury Brown maintained a Buy rating on Solid Biosciences today. The company’s shares closed last Wednesday at $7.72.
According to TipRanks.com, Brown is a 3-star analyst with an average return of
Currently, the analyst consensus on Solid Biosciences is a Strong Buy with an average price target of $17.00, which is an 112.5% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $14.00 price target.
See today’s best-performing stocks on TipRanks >>
Universal Health (UHS)
In a report released today, A.J. Rice from UBS maintained a Buy rating on Universal Health, with a price target of $320.00. The company’s shares closed last Wednesday at $186.24.
According to TipRanks.com, Rice is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Universal Health with a $247.38 average price target, which is a 33.8% upside from current levels. In a report issued on February 25, Barclays also maintained a Buy rating on the stock with a $268.00 price target.
